Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the program is to provide access to TAS-102 to patients with metastatic
colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy
with TAS-102 and in whom therapy with TAS-102 is clinically indicated.